A Phase 1, Open-label, Randomized, Four-way Crossover Study to Assess the Relative Bioavailability of Two Phase 3 LY4100511 (DC-853) Tablet Formulations Compared With the Phase 2 LY4100511(DC-853) Tablet Formulation, With and Without a Proton Pump Inhibitor in Healthy Participants
Latest Information Update: 15 Sep 2026
At a glance
- Drugs DC-853 (Primary)
- Indications Immunological disorders; Plaque psoriasis; Psoriasis
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
Most Recent Events
- 09 Sep 2026 Actual primary completion date changed to 8 Apr 2025.
- 09 Sep 2026 Status changed from active, no longer recruiting to discontinued.
- 16 Jul 2026 Planned End Date changed from 1 Jul 2026 to 1 Aug 2026.